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Abstract
 
The inverse relationship between serum albumin concentration and its half-life suggested to early
workers that albumin would be protected from a catabolic fate by a receptor-mediated mechanism
much like that proposed for IgG. We show here that albumin binds FcRn in a pH dependent
fashion, that the lifespan of albumin is shortened in FcRn-deficient mice, and that the plasma
albumin concentration of FcRn-deficient mice is less than half that of wild-type mice. These
results affirm the hypothesis that the major histocompatibility complex–related Fc receptor
protects albumin from degradation just as it does IgG, prolonging the half-lives of both.
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Introduction
 
Albumin is a heart-shaped molecule of 67 kD that constitutes
two-thirds of the protein mass of serum. Likened to a
tramp steamer, it transports a great assortment of molecules
such as fatty acids, bile acids, eicosanoids, vitamins, hormones,
ions, toxins, and drugs. As well albumin endows blood
with most of its colloid osmotic pressure and is the major
pH buffering protein of serum (1).
For nearly a half century it has been known that the
fractional catabolic rate of albumin is directly related to its
serum concentration (2). Thus, the half-life of infused albumin
in analbuminemic patients is as long as 115 d compared with
20 d in the normal individual (3). This same direct relationship
of concentration to catabolism is characteristic of IgG, but
not of several other serum proteins such as fibrinogen,
transferrin, haptoglobin, IgA, and IgM (4, 5). Proposing an
explanation for the direct relationship, Brambell presented
the now widely held hypothesis that IgG is protected from
degradation by an Fc receptor–mediated mechanism (6).
Specifically, IgG is pinocytosed along with other serum
proteins by many cells of the body and is transported to an
acidic intracellular compartment where it encounters FcRn,
the MHC-related Fc receptor that binds IgG with high
affinity at low pH but shows no affinity at physiologic pH
(reference 7; for reviews, see references 8 and 9). FcRn
effectively diverts IgG from a degradative fate in lysosomes,
instead transporting it back to the cell surface where under
the influence of neutral pH it dissociates from the receptor
and is free to recycle. The lifespan of IgG is thus prolonged
relative to other serum proteins not similarly protected.
Despite this progress in understanding IgG catabolism,
the mechanism by which albumin half-life is prolonged
has not been explored.
In 1966, however, Schultze and Heremans conjectured
that a mechanism identical to that proposed by Brambell
for protecting IgG from degradation could be applied to
albumin as well (5). Such a hypothesis has three testable
predictions: that FcRn binds albumin in addition to IgG;
that FcRn-deficient mice catabolize albumin more rapidly
than normal mice; and that the serum albumin concentration
in FcRn-deficient mice is low. We have affirmed all three
of these predictions.
 
Materials and Methods
 
Purification of shFcRn and srFcRn.
 
The Chinese hamster ovary
 
(CHO)
 
*
 
 cell line 2G11 secreting recombinant soluble human Fc
receptor
 
 (
 
shFcRn), given by Dr. Pamela Bjorkman (California
Institute of Technology, Pasadena, CA), was cultured in custom
 
Address correspondence to Dr. Clark Anderson, Department of Internal
Medicine, The Ohio State University
 
, 
 
415 HLRI, 473 West 12 Ave.,
Columbus, OH 43210. Phone: 614-247-7654; Fax: 614-247-7669; E-mail:
anderson.48@osu.edu
 
*
 
Abbreviations used in this paper:
 
 b2m,
 
 
 
 
 
2-microglobulin; CHO, Chinese
hamster ovary; HSA, human serum albumin; OG, Octyl-
 
 
 
-D-Glucopy-
ranoside; sRSA, rat serum albumin; shFcRn, soluble human Fc receptor
(neonatal).T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
316
 
FcRn Protects Albumin
 
 
 
 MEM Earle’s medium (Irvine Scientific) with 5% FCS, penicil-
lin, streptomycin (all from GIBCO BRL), and MSX (Sigma-
Aldrich) essentially as described (10). Culture supernatant from
these cells containing shFcRn (
 
 
 
10 mg/liter) in 500 ml batches
was acidified to pH 5.8 and applied to a chromatography column
containing Sepharose-hIgG (10 ml at substitution ratio of 10 mg
hIgG per ml Sepharose) as described (10). Bound shFcRn was
eluted at pH 8.1 into 1.0 ml fractions that were assessed for protein
content by bicinchoninic acid (BCA) protein assay kit (Pierce
Chemical Co.) or UV absorption at 280 nm. shFcRn was further
purified by anionic exchange chromatography as described (10).
srFcRn was purified from culture supernatant of the CHO cell line
6J23100, also given by Dr. Bjorkman, as described (11).
 
Quantification of shFcRn-associated BSA.
 
The fractions con-
taining the protein peak of eluted shFcRn were pooled and along
with graded amounts of a BSA standard (Pierce Chemical Co.)
were analyzed on duplicate SDS-polyacrylamide sizing gels as de-
scribed (12). One gel was stained with Coomassie blue and the
other was processed for immunoblotting with anti-BSA antibody
(Sigma-Aldrich) as described (12). The band densities in the Coo-
massie stained gels were quantified with a Gel Doc system and in
immunoblots with a Fluor-S-Max multi-imager using Quantity
One software (Bio-Rad Laboratories).
 
Plasma Protein Concentrations.
 
Albumin and Ig concentrations
of mouse plasma samples were determined using sandwich ELISA
kits (Bethyl Labs) with reference to standard concentrations of
purified proteins as follows: for albumin (Inter-Cell; Cat. no.
F301–1) determined by UV absorption at 280 nm using E
 
1%
280
 
 
 
 
 
5.7, for IgG isolated from pooled normal mouse serum (Sigma-
Aldrich; no. I 5391) determined by UV absorption at 280 nm us-
ing E
 
1%
280
 
 
 
 
 
 14.0, for IgM purified from MOPC 104E ascites
(ICN Biomedicals; no. 50335) measured by BCA assay using as a
standard BSA quantified by UV absorption at 280 nm, E
 
1%
280
 
 
 
 
 
6.6. For IgA the reference serum from the supplier was used as
the standard. Plasmas were obtained from The Jackson Labora-
tory where mice were housed in specific pathogen free barrier
facilities. Plasmas were obtained from six mice 8 wk old of a 
 
 
 
2-
microglobulin 
 
(
 
b2m) KO strain (B6.129P2-
 
B2m
 
tm1Unc
 
; The Jack-
son Laboratory; no. 002087) and six mice 8 wk old of their wild-
type control strain (C57BL/6J; The Jackson Laboratory; no.
000664); from eight mice of an FcRn 
 
 
 
-chain KO strain
(B6.129X1/SvJ-
 
Fcgrt
 
Tm1Dcr
 
(N6)) (unpublished data) ages 5 wk (
 
n
 
 
 
 
 
3) and 6 wk (
 
n
 
 
 
 
 
 3) and 8 wk (
 
n
 
 
 
 
 
 2), and 8 mice of their con-
trol strain (C57BL/6J, ages 6 wk (
 
n
 
 
 
 
 
 3) and 10 wk (
 
n
 
 
 
 
 
 5); and
from FcRn 
 
 
 
-chain KO mice 8 wk old expressing a hFcRn
transgene (B6;129-FcRn
 
 
 
/
 
 
 
, hFcRn line 276) and an equal num-
ber of transgene negative FcRn KO, littermate controls, 5 in each
group. The human FcRn transgene for line 276 was derived from
a human FcRn cDNA construct cloned into Vector E (provided
by Dr. William Sly, St. Louis University School of Medicine, St.
Louis, MO). This transgene is driven by a CMV enhancer and a
chicken 
 
 
 
-actin promoter, and results in ubiquitous expression as
determined by quantitative PCR procedures and Western blot
analysis (unpublished data). A similar transgenic has been de-
scribed (unpublished data). 
 
pH-dependent Binding of shFcRn and srFcRn to Immobilized
Ligands.
 
Human serum albumin (HSA; catalog no. A-8763),
hIgG (catalog no. I-4506), fish gelatin (catalog no. G-7765), and
recombinant sperm whale myoglobin (catalog no. M7526), all
from Sigma-Aldrich, and rat serum albumin
 
 (
 
RSA; catalog no.
55952) from ICN Biomedicals/Cappel, were immobilized on
CNBr-activated Sepharose 4B (Amersham Biosciences) at 10 mg
protein/ml Sepharose. Sepharose-Tris was prepared by blocking
 
the reactive groups of CNBr-activated Sepharose 4B with 0.1 M
Trizma base, 0.5 M NaCl, pH 8. Sepharose beads linked to HSA,
hIgG, fish gelatin, myoglobin, Tris, or RSA (20 
 
 
 
l beads equiva-
lent to 
 
 
 
180 
 
 
 
g linked protein) were washed with 50 mM Tris,
150 mM NaCl buffer at pH varying from 5–8 containing 0.1%
fish gelatin, and were then incubated for 2 h at room temperature
with 80 
 
 
 
l of shFcRn (final concentration 150 
 
 
 
g/ml) in 50 mM
Tris, 150 mM NaCl, 0.1% fish gelatin buffer of appropriate pH.
Unbound protein was washed away using 50 mM Tris, 150 mM
NaCl, 0.1% fish gelatin buffer of appropriate pH. Bound protein
was eluted by boiling with SDS-containing sample buffer (60
mM Tris, pH 6.8, 2.3% SDS, 10% glycerol, 0.01% bromophenol
blue) containing 1% 2-mercaptoethanol, and was analyzed on a
SDS polyacrylamide gel followed by immunoblotting with anti-
hFcRn (anti-H1) or anti-rFcRn (1G3; reference 13) antibodies
and enhanced chemiluminescence as described (14). The amount
of shFcRn or srFcRn bound to the respective immobilized
ligands at various pH values was quantified as described above
and plotted as a percentage over the amount of protein loaded
versus pH. Eluting at pH 8.1, rather than with SDS, and precipi-
tating with trichloroacetic acid
 
 (
 
TCA) gave similar results. The
amounts of HFE (given by Dr. Pamela Bjorkman) bound to
Sepharose-HSA or –myoglobin were analyzed by immunoblot-
ting with anti-b2m antibody (catalog no. sc8362; Santa Cruz
Biotechnology, Inc.).
 
Albumin-shFcRn Interaction in the Presence of Octyl 
 
 
 
-D-glucopy-
ranoside.
 
Sepharose-HSA, hIgG, and Tris were prepared as de-
scribed above for binding at varying pH. Sepharose beads linked
to HSA, hIgG, and Tris (20 
 
 
 
l beads equivalent to 
 
 
 
180 
 
 
 
g
linked protein) were washed with 50 mM Tris, 150 mM NaCl,
pH 6.0 buffer with 0.1% fish gelatin and varying concentrations
of Octyl-
 
 
 
-D-Glucopyranoside (OG; catalog no. O-8001;
Sigma-Aldrich), and were then incubated for 2 h at room tem-
perature with 80 
 
 
 
l of shFcRn (final concentration 100 
 
 
 
g/ml)
in 50 mM Tris, 150 mM NaCl, 0.1% fish gelatin pH 6.0 buffer of
appropriate detergent concentration. Unbound protein was
washed away using 50 mM Tris, 150 mM NaCl, 0.1% fish gelatin
pH 6.0 buffer of appropriate detergent concentration. Bound
protein was eluted, analyzed on a SDS polyacrylamide gel, and
quantified as described for the pH experiments. The amount of
shFcRn bound to the respective immobilized ligands at various
detergent concentrations was plotted as a percentage of total
shFcRn versus detergent concentration.
 
Measurement of Rate of Albumin Decay in FcRn-deficient Mice.
 
All animal studies were approved by the Institutional Review
Board. The following murine proteins were used, all purified by
a combination of ammonium sulfate precipitation, ionic ex-
change chromatography, affinity chromatography, and gel filtra-
tion; ethanol precipitation was avoided. Albumin (F-301–1, lot
0786) was supplied by Inter-Cell Technologies, Inc. All Ig were
obtained from ICN Biomedicals. IgG was an IgG1 myeloma
MOPC21 (catalog no. 64335). IgA was myeloma TEPC15 (cata-
log no. 50326). IgM was myeloma MOPC 104E (catalog no.
50335). These proteins were dialyzed against pH 7.2 buffer con-
taining 50 mM NaCl and 100 mM phosphate, and were radioio-
dinated by the chloroglycouril method (15) using 5–10 
 
 
 
g CGU
per 50–100 
 
 
 
l protein solution. Molar substitution ratios were
0.1–0.2 atoms of 
 
125
 
I per molecule of protein. Two strains of
FcRn-deficient mice were used. b2m KO mice (B6.129P2-
 
B2m
 
tm1Unc
 
) and its relevant WT control strain (C57BL/6) were
obtained from The Jackson Laboratory. FcRn 
 
 
 
-chain KO mice
were used as well. Development of this strain is described in a
separate publication which shows that the FcRn 
 
 
 
-chain geneT
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was disrupted by the targeting vector as predicted; that the mouse
expresses no 
 
 
 
-chain mRNA or protein; and that it manifests the
predicted phenotype, failing to transport IgG across the neonatal
gut, degrading IgG at an accelerated rate, and being IgG deficient
(unpublished data). Mice at age 3 mo were infused via tail veins
with 150 
 
 
 
l radioiodinated protein (2–20 
 
 
 
 10
 
6
 
 cpm, or 1–12 
 
 
 
g
protein) diluted in phosphate buffered saline containing 10% nor-
mal mouse serum (ICN Biomedicals). Within 10 min of infusion
(time zero) and daily through 120 h, 40 
 
 
 
l blood was sampled via
heparinized tubes from the retro-orbital plexus. Plasma was har-
vested; the proteins in 15 
 
 
 
l plasma were precipitated in 12.5%
TCA; radiolabeled proteins in the pellets were counted in a
gamma counter and were always 
 
 
 
95% of the total radioactivity.
The plasma radioactivity, normalized for dose, was plotted on a
log scale versus time.
Pharmacokinetic parameter values were determined from the
dose-normalized plasma protein concentration-time profiles us-
ing WinNonlin software (Pharsight Corp.) and the noncompart-
mental analysis method. The area under each plasma concentra-
tion-time curve (AUC) was calculated using the logarithmic
trapezoidal method with the area beyond the last measured value
(C
 
p,last
 
) estimated from C
 
p,last
 
/
 
 
 
z
 
 where 
 
 
 
z
 
 was the slope of a line
fitted by least squares to a plot of the log concentration-time val-
ues that appeared to fall along a straight line. Clearance (CL) val-
ues for the proteins were calculated from CL 
 
 
 
 dose/AUC,
where dose was cpm infused. Half-life (t
 
1/2
 
) was calculated from
ln 2/
 
 
 
z
 
. The mean t
 
1/2
 
 and its standard deviation were calculated
using the jack knife technique as described (16).
To calculate the rates of biosynthesis and biodegradation of the
proteins, it was assumed that the endogenous proteins were at
steady state; i.e., that their rates of biosynthesis equaled their rates
of biodegradation. These rates were estimated as the product
CL 
 
 
 
 C
 
p,ss
 
, where C
 
p,ss
 
 was the steady-state plasma concentration
of protein, taken from our measurements.
The radioiodinated protein in plasma at 120 h after infusion of
both the FcRn 
 
 
 
-chain KO mouse and its WT control mouse
was identified as albumin by its mobility on SDS-PAGE (17).
Specifically, the 120 h plasma samples were analyzed in parallel
with radioiodinated proteins (albumin, IgA, IgM) used for infu-
sion, loading nearly equal cpm in each lane. To deal with the
mobility artifact caused by the high concentration of endogenous
albumin in plasma, we added unlabeled albumin in the form of
normal mouse serum to the infusion protein samples, thereby
equalizing the total albumin content of the samples. Radioactive
signals in the gel were recorded with a Fluor-S-Multi Imager
(Bio-Rad Laboratories).
 
Calculations.
 
Using the apparent steady-state serum concen-
trations in mg/ml from Fig. 4 we calculate an albumin/IgG molar
plasma ratio of 509 in WT mice in the b2m KO experiments, as
follows: ratio 
 
 
 
 (albumin concentration 
 
 
 
 albumin gram molec-
ular weight) 
 
 
 
 (IgG concentration 
 
 
 
 IgG gram molecular
weight) 
 
 
 
 (31.7 
 
 
 
 67,000) 
 
 
 
 (0.137 
 
 
 
 150,000) 
 
 
 
 509. The
biosynthetic rate of albumin, calculated as the product of CL 
 
 
 
albumin concentration, in the b2m KO mouse was 0.110 ml/h 
 
 
 
11.5 mg/ml 
 
 
 
 1.27 mg/h, and in the WT mouse was 0.072
ml/h 
 
 
 
 31.7 mg/ml 
 
 
 
 2.28 mg/h. The ratio, then, of WT/KO
biosynthetic rates is 2.28 
 
 
 
 1.27 
 
 
 
 1.8.
 
Comparisons of Ig Concentrations.
 
It would be hazardous to
compare the absolute values of our Ig concentrations with those
of other laboratories because of differences in age and strain and
housing conditions of the mice and because of differences in assay
reagents. Likewise, within our own data of Fig. 5 one should
only cautiously compare between Ig classes because the assays for
 
each class may vary in efficiency, each requiring its own standard
and its own anti-Ig antibody. Nevertheless, it would appear that
our IgG values (113–139 
 
 
 
g/ml) are not disparate from what has
been reported. IgG levels are well known to be very low in mice
reared in relative germ-free conditions similar to ours housed in
specific pathogen free facilities. Specifically, IgG concentrations
in 8-wk-old C57BL/6 mice were reported to be 33 
 
 
 
g/ml (18),
while Balb/c mice gave values ranging from 3 
 
 
 
g/ml (19) to 56
 
 
 
g/ml (20). Values as high as 20 mg/ml have been reported for
mice raised conventionally (21). Similarly, while our reported
IgA concentrations might seem high (237–482 
 
 
 
g/ml), others
have reported concentrations far in excess of ours, e.g., 0.6–2.3
mg/ml (22) and 1–3 mg/ml (21). Thus, we argue that compari-
sons should legitimately be made only for each antibody between
the two strains of mice (KO and WT). Likewise, comparisons be-
tween albumin and IgG concentrations should be considered ap-
proximate.
Results
First, we found fortuitously that albumin binds FcRn to
form a tri-molecular complex with IgG. Upon eluting re-
combinant soluble human FcRn (shFcRn) from an IgG af-
finity matrix by raising the pH from 5.8 to 8.1 we noted a
67-kD protein copurifying in abundance with shFcRn. In
a typical experiment, acidified culture supernatant of a
transfected cell line (CHO) secreting shFcRn (10), a het-
erodimer of the extracellular portion of the  -chain and
 2-microglobulin (b2m), was passed through an affinity
column of Sepharose-human IgG (hIgG). The protein
peak in several fractions of the pH 8.1 eluate was analyzed
by electrophoresis on a sizing gel (Fig. 1 A). Three promi-
nent bands were apparent: the 35-kD truncated shFcRn
 -chain identified in other experiments by immunoblotting;
a 12-kD b2m run off the gel shown, identified also by im-
munoblotting in other experiments; and a 67-kD band.
Elution of the 67-kD molecule was dependent on the pres-
ence of shFcRn; i.e., it was not affinity purified in like
manner from culture supernatant of CHO cells not secret-
ing shFcRn. It was apparent in Fig. 1 A and in many such
experiments that while the elution profiles of shFcRn and
the 67-kD protein overlapped, the 67-kD protein peak
eluted at a slightly more acidic pH (fraction 6) than did
shFcRn (between fraction 6 and 7). This consistent lag sug-
gested that the 67-kD protein interacted with shFcRn in a
pH dependent fashion, just as did IgG. The 67-kD mole-
cule was not simply eluting bound to shFcRn; rather, the
tri-molecular complex was dissociating into its three com-
ponents at basic pH.
The 67-kD protein (lane E of Fig. 1 B, top) had the mo-
bility of BSA by reference to BSA standards in adjacent lanes
and was identified as BSA by immunoblotting (Fig. 1 B, bot-
tom). Further, densitometric quantification of both the Coo-
massie stained image (Fig. 1 B, top) and the immunoblotted
image (Fig. 1 B, bottom) gave virtually identical values (Fig.
1 C), suggesting that this band was entirely BSA. In a series
of experiments the molar ratio of shFcRn to BSA in eluates
has varied from close to unity to  10 for reasons that so far
elude us. The obvious source of BSA was the 10% FCST
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present in the growth medium of the CHO cells. It is im-
portant to note that no proteins other than BSA were copu-
rified with shFcRn from FCS despite many being present in
concentrations far in excess of the  10  g/ml of shFcRn.
Using a different approach, we assessed more rigorously
the acid dependence of albumin–shFcRn interaction by
comparing the capacity of shFcRn to bind to both
Sepharose-human serum albumin (HSA) and Sepharose-
hIgG in buffers ranging from pH 5.0–8.0. After binding
to immobilized ligands, shFcRn was eluted and the eluted
protein was quantified by densitometry of anti-FcRn im-
munoblots (Fig. 2, A–D). Binding of shFcRn to both
Sepharose-HSA (Fig. 2 A) and Sepharose-hIgG (Fig. 2 B)
was pH dependent, being maximal at pH 5.0 with  80%
of total receptor being adsorbed from solution; binding
was nil at pH 7.0 through pH 8. At intermediary pH val-
ues the binding of shFcRn was slightly greater to HSA at
lower pH and slightly greater to hIgG at higher pH,
noted both in Fig. 2 D and in two other similar experi-
ments not shown; the differences are subtle, however, and
will require further study. Binding to Sepharose-Tris (Fig.
2 C) and to both Sepharose-fish gelatin and Sepharose-
myoglobin (unpublished data) was nil throughout the pH
range. In similar experiments we have found that shFcRn
binds to immobilized albumin from rat, mouse, and bo-
vine (unpublished data).
Assessing FcRn from another species, the rat, we noted
that soluble rat FcRn (srFcRn) bound Sepharose-linked rat
albumin (Fig. 2 E) at acidic pH although to a lesser extent
than to Sepharose-hIgG (Fig. 2 F). srFcRn did not, how-
ever, bind Sepharose-human and -bovine albumin, nor did
it bind Sepharose-Tris or -myoglobin (unpublished data).
Assessing another nonclassical MHC1 family member,
namely, HFE (23), implicated in hereditary hemochroma-
tosis, we found no binding of HFE to Sepharose-HSA
while shFcRn simultaneously bound (Fig. 2 G). Neither
HFE nor shFcRn bound Sepharose-myoglobin (Fig. 2 H).
It would be predicted that we should be able to purify
native (as opposed to recombinant) FcRn on immobilized
albumin at the appropriate pH. However, our attempts to
affinity adsorb native FcRn from detergent lysates of
FcRn expressing tissue such as placenta, skin, and an
FcRn-expressing cell line (MRC5) have so far failed, al-
Figure 1. Copurification of
BSA and shFcRn by affinity
chromatography on Sepharose-
hIgG. (A) Culture supernatant
from CHO cells secreting re-
combinant shFcRn was acidified
to pH 5.8 and applied to a
Sepharose-hIgG chromatography
column. Bound shFcRn was
eluted at pH 8.1. Six fractions of
the elution peak (4–9) were ana-
lyzed by SDS-PAGE under re-
ducing conditions and Coomassie
blue staining. The molecular
weight markers (M, in kD) allow
identification of the  -chain of
shFcRn at  35kD and another
copurifying protein at 67kD. (B)
The elution peak (E) from a
Sepharose IgG column was ana-
lyzed by SDS-PAGE on two
identical gels along with molecu-
lar weight standards (M) and
graded amounts (lanes 1–8; in  g
per lane) of BSA. One gel (top)
was stained with Coomassie
blue and the other (bottom)
was immunoblotted with anti-
BSA antibody. (C) The band
densities in the Coomassie
stained gel ( ) and the immu-
noblot ( ) of B were plotted
(on y-axis) against BSA quan-
tity (on x-axis). The left arrow
indicates the eluate density on
the Coomassie stained gel while the right arrow indicates the density
of the eluate on the immunoblot. Three separate experiments have
given equivalent results.
Figure 2. pH-dependent binding of FcRn to immobilized albumin.
Sepharose (S)-HSA, S-IgG, S-Tris, S-fish gelatin (see Materials and
Methods), or S-RSA were incubated with shFcRn or srFcRn at varying
pH as shown. Bound soluble FcRn were eluted and were quantified by
immunoblotting with anti-FcRn antibody. Immunoblots of binding of
shFcRn to S-HSA, S-IgG, and S-Tris at pH values indicated are shown in
A, B, and C, respectively. Immunoblot of binding of srFcRn to S-RSA is
shown in E. The positions of molecular weight markers (M, in kD) are
shown. Lane 1 in all the gels contained 15  g soluble FcRn, the
amount added to every adsorbent sample. Lane 2 in each case shows the
eluate from Sepharose-ligand in the absence of FcRn. The shFcRn
bands were quantified and are plotted in panel D vs. pH. Three distinct
experiments have given equivalent results. srFcRn band densities are
plotted in panel F vs. pH. A second experiment with srFcRn gave
equivalent results. G and H show binding of HFE to S-HSA and
S-myoglobin. Lanes 1 and 2 show amounts of shFcRn and HFE added
(15  g) to adsorbent samples. Bound protein was eluted and quantified
by blotting with anti-b2m antibody.T
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though the native receptor is readily adsorbed by immo-
bilized IgG (14, 24, 25). Offering a potential explanation
for this observation, we found that nonionic detergent
(either OG or TX100) completely inhibits capture of re-
combinant shFcRn with immobilized albumin. As Fig. 3
shows, complete blockade (97%) was achieved with as lit-
tle as 22 mM OG (essentially, the critical micellar con-
centration), far less than the concentration used for tissue
or cell dissolution (86 mM). In contrast, the capture of
shFcRn with immobilized IgG was preserved and in fact
was enhanced in OG (2.5-fold at 22 mM and 3.2-fold at
86 mM). Whether detergent interferes with the albumin
binding site or the receptor binding site, or both, we have
not yet been able to ascertain.
Testing the second prediction of the Schultze/Heremans
hypothesis, that albumin will be degraded more rapidly in
mice deficient in FcRn, we infused radioiodinated mouse al-
bumin intravenously into mice of two strains deficient in
FcRn, both the b2m KO strain (26) and the FcRn  -chain
KO strain (unpublished data). By sampling blood daily for
120 h we calculated the albumin decay curves (plotted in Fig.
4, A–E) and the half-lives from the  - or elimination-phase
Figure 3. Detergent inhibits shFcRn albumin interaction. Sepharose
(S)-HSA, S-IgG and S-Tris (A–C) were incubated with shFcRn in a pH
6.0 buffer containing indicated concentrations of OG as shown. Bound
shFcRn was eluted and quantified by immunoblotting with anti-FcRn
antibody. The positions of molecular weight markers (M, in kD) are
shown. Lane 1 in each case shows the eluate from Sepharose-ligand in the
absence of shFcRn. Lane 2 in all the gels contained 10  g shFcRn, the
amount added to every adsorbent sample. The shFcRn bands were
quantified and plotted in panel D vs. OG concentration. Similar results
were obtained in another experiment.
Figure 4. Decay of radioiodinated albumin in FcRn-deficient mice. A–C
show the concentration of plasma radioactivity remaining at indicated times
after intravenous infusion of b2m KO mice (open circles) and their WT
control mice (filled circles) of radioiodinated albumin, IgA, and IgG,
respectively. D and E show results for FcRn  -chain KO (open squares)
and WT control mice (filled squares). Mean half-lives (t1/2) of  -phase
decay in hours are shown with SD. The numbers of mice in each experiment
are indicated by (n). Using a repeated measures ANOVA model to
compare results between b2m KO and WT animals, we analyzed the
logarithm of the ratio of the daily values with time 0 values (log ratios
of plasma cpm). We found a statistically significant difference between
the two groups of animals in the half-lives of both albumin and IgG
during days 1 to 5 (both P values  0.0001). IgA and IgM (text only)
values in the two strains of mice were not significantly different from
one another (P   0.4 and 0.9, respectively). For the experiment with
FcRn  -chain KO and WT, the P value for albumin was  0.0001
while that for IgA was 0.3. F shows an autoradiograph of an SDS-
PAGE of the radiolabeled proteins in the plasma of WT (lane 3) and
FcRn  -chain KO (lane 4) mice at 120 h after infusion of radiolabeled
albumin. The positions of molecular weight markers (M, in kD) are
shown along bottom. Lanes 1, 2, 5, and 6 contain infused radiolabeled
albumin equalized for the endogenous albumin content of the plasma
samples by the addition, respectively, of 0, 0.75, 0.5, and 1.5  l normal
mouse plasma. Lanes 7 and 8 contain radioiodinated IgA containing 0 and
1.5  l mouse serum, respectively. Lane 9 contains radioiodinated IgM.
The experiment was repeated with 120 h plasma from a b2m KO mouse
and WT control with equivalent results. T
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of decay (having no data for the first 24 h save for the zero
point, we ignore the  - or distribution-phase calculations, al-
though in a single pilot experiment with 3 mice we note t1/2
of the  -phase to be  4 h.) It can be seen that the half-life of
albumin is shortened in the b2m KO strain (t1/2 25 h vs. 35 h
in WT, Fig. 4 A) whereas the half-lives of IgA are not differ-
ent in the two strains (t1/2 23 h, Fig. 4 B). IgM decay curves
were superimposable on those of Fig. 4 B (t1/2 23   1 in both
strains of mice). As well, the half-life of IgG is shortened (t1/2
19 h vs. 95 h in WT, Fig. 3 C), as has already been reported
(22, 27, 28). Others have noted but not explored a modest
increase in the decay rate of albumin in b2m KO mice (27,
29). As b2m KO mice are not albuminuric (30, 31), we sug-
gest the rapid decay represents degradation.
Likewise, in the FcRn  -chain KO strain (Fig. 4, D and
E), albumin half-life is shortened (t1/2 24 h vs. 39 h in WT,
Fig. 4 D) while that of IgA is not (Fig. 4 E); and, although
not shown here, IgG half-life is shortened (unpublished
data). Because the amount of radioiodinated protein re-
maining at the end of the 120 h experiment was a small
fraction of that infused at time zero, we considered experi-
mentally whether the remaining labeled protein was indeed
albumin. Analyzing the 120 h plasma samples from FcRn
 -chain KO and WT mice by SDS-sizing gel electro-
phoresis and PhosphorImaging, we noted (Fig. 4 F) that the
radioactive bands from both KO and WT mice (lanes 3 and
4) were indistinguishable in mobility from the 125I-albumin
infusion samples adjusted for the high endogenous albumin
content of the plasma samples by the addition of exogenous
normal mouse plasma (lanes 2, 5, 6). This observation
largely eliminates the possibility that decay of a small con-
taminant of the albumin preparation was responsible for the
differences noted in decay rates.
It would be predicted by the Schultze/Heremans hy-
pothesis that a lower serum albumin concentration and/or
an increased albumin biosynthetic rate in FcRn-deficient
mice would accompany an accelerated rate of degradation.
Measuring the former we found that in both FcRn-defi-
cient strains tested the serum albumin concentrations were
 45% of that in control strains (Figs. 5 A and 4 B). IgA and
IgM concentrations were not diminished in b2m KO mice
compared with WT mice (Fig. 5 A), and in fact were mar-
ginally significantly higher. IgA and IgM concentrations
were not different statistically between the FcRn  -chain
KO and WT strains (Fig. 5 B). As has been shown before,
IgG concentrations were low in the FcRn-deficient strains
compared with WT strains (22, 27; unpublished data). 
The relative albumin deficiency in the FcRn  -chain
KO mouse was corrected (increased by 46%) by the ex-
pression of an hFcRn transgene (Fig. 5 C), while IgG,
IgM, and IgA concentrations were not affected. This result
eliminates the possibility that genes flanking the FcRn tar-
geting vector in the original host embryonic stem cell are
responsible for the noted rapid decay of albumin in the
FcRn  -chain KO mouse. Moreover, this result suggests
that the human FcRn binds and protects murine albumin
from degradation. We have incidentally found, as corrobo-
rated by the IgG data of Fig. 5 C, that the human trans-
genic receptor is not as promiscuous in its handling of IgG
of different species as it is in its handling of albumin of dif-
ferent species; i.e., it is unable to bind and protect murine
IgG from degradation although its presence corrects the
rapid decay rate of infused human IgG in the FcRn  -chain
KO mouse (unpublished data). 
Discussion
These three independent results, we conclude, affirm the
hypothesis that FcRn binds not only IgG but albumin as
well, salvaging both proteins from a degradative fate and
extending their lifespans.
Our observation that FcRn binds albumin in the same
pH dependent fashion as it binds IgG suggests that the
mechanism of protection of albumin by FcRn is identical
to that of IgG, as postulated by Shultze and Heremans. We
Figure 5. Plasma concentrations of albumin, IgG, IgA, and IgM in
FcRn-deficient mice and in FcRn  -chain–deficient mice expressing a
hFcRn transgene. Concentrations were determined by a sandwich
ELISA. The specific KO, WT, transgenic strains and ages are given in
Materials and Methods. Values are the means   standard errors. P values
are from Student’s t test. Alternative significance statements using the
nonparametric Mann-Whitney test give comparable results. (A) b2m KO
(hatched bars) and corresponding wild-type (empty bars), six mice in each
group. (B) FcRn  -chain KO (hatched bars) and corresponding wild-
type (empty bars), eight mice in each group. (C) FcRn  -chain KO mice
either expressing (crosshatched bars) or not expressing (hatched bars) a
hFcRn transgene, five mice in each group.T
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envision that albumin is pinocytosed nonspecifically along
with IgG from the extracellular milieu, is transported to
acidic endosomes where it binds FcRn, is thereby diverted
from the lysosomal degradation pathway, is exocytosed in-
tact, and is then free to transit again, thus extending its half-
life. That this albumin protection mechanism is widespread
among animals is suggested by our data from three species,
i.e., binding data using both human and rat FcRn, and al-
bumin decay rates and plasma concentrations in the mouse.
Further, the fact that the t1/2 of albumin in both KO strains
compared with WT were approximately equal would sug-
gest that FcRn accounts for the entire protection effect
conferred by b2m-associated proteins; i.e., no other MHC
related molecule need be implicated in the protection from
decay of albumin. The failure of HFE to bind albumin
(Fig. 2 G) supports this conclusion.
Using the kinetic data of Fig. 4 and the apparent steady
state protein concentrations recorded in Fig. 5 we can
compare the relative capacity of FcRn to protect albumin
and IgG from degradation. From the dose administered
and the rate of elimination we compute albumin clearance
for the b2m KO strain and its relevant WT control strain
to be 0.110 and 0.072 ml/h, respectively; while for IgG
the respective clearances for the two strains are 0.043 and
0.015 ml/h. We reason that the fraction of protein saved
per day by FcRn would be directly related to the differ-
ence between the clearances in WT and KO strains;
namely, 0.038 ml/h for albumin and 0.028 ml/h for IgG.
Based on a molar ratio of serum albumin to IgG of 509
from Fig. 4 A, we calculate (see Materials and Methods)
that for every molecule of IgG saved from degradation by
FcRn, almost 700 molecules of albumin are saved from
degradation! Thus, what would appear to be a minor dif-
ference in the rate of albumin decay between WT and KO
is magnified by the widely disparate serum concentrations
of the two proteins to reveal an extraordinary capacity of
FcRn to handle albumin relative to IgG. The low IgG
concentrations in these mice are likely the result of patho-
gen free housing (see note on comparisons of Ig concen-
trations in Materials and Methods). Yet, were we to ex-
trapolate to the human, where the concentrations of these
two proteins are not so disparate (IgG and albumin, 10 and
40 mg/ml, respectively), the molar ratio of albumin to IgG
saved by FcRn would be 12, still many more albumin than
IgG molecules.
We can further apply the kinetic data of Fig. 4 to a calcu-
lation of the albumin biosynthetic rate in FcRn-deficient
mice where biosynthetic rate (mg/h)   clearance (ml/h)  
steady state plasma concentration (mg/ml) from our steady
state data. We find for the b2m KO strain and its relevant
WT control that the biosynthetic rate in the WT is 1.8-fold
greater than that of the KO (2.28 mg/h vs. 1.27 mg/h). This
result implicates FcRn in the albumin biosynthetic pathway.
The question emerges whether FcRn transports albumin
as it does IgG from mother to offspring. Brambell in his 1970
monograph summarizing this entire area at that time asserted
that in most if not all animals albumin was transmitted along
with IgG although to a lesser extent (6). The published data,
however, are old, scant, sketchy, and conflicting; and it
would appear that interest in examining albumin transport
was very early eclipsed by the more compelling question of
IgG transport. This issue will require revisiting.
Whether FcRn plays a role in the transit of albumin be-
tween the vascular and the extravascular spaces is an enticing
question. In support of this notion, endothelium has not
only been suggested as the likely main site of albumin degra-
dation (32), implying abundant uptake, but it also has been
shown to be a site of FcRn expression (22, 33; unpublished
data). One prediction of such a hypothesis is that the rate of
distribution to the extravascular space after an albumin infu-
sion may be slowed in FcRn-deficient mice.
We note that albumin is found in the lamprey and so pre-
dates immunoglobulin in evolutionary history (1, 34). More-
over, elements of the albumin family appear as ancient as
Phylum Echinodermata (35). Thus, we would suggest the
existence of an FcRn precursor that bound only albumin as
the evolutionary antecedent to the present day FcRn that
binds both albumin and IgG. It seems not too far-fetched to
conjecture that such an antecedent may have evolved as well
into an MHC-like peptide-binding molecule.
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